Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve clinical outcomes and quality of life for people living with corneal and ocular surface diseases. \n\nBrightstar Therapeutics is the first company to offer a long-term solution for persistent epithelial defects, and partial limbal stem cell deficiency through its advanced corneal allograft, BrightMEM.